Results 21 to 30 of about 109,328 (235)

Leishmaniasis [PDF]

hautnah dermatologie, 2015
ZusammenfassungInfektionen mit Leishmanien gehören zu den Top 3 der häufigsten Reisedermatosen. Je nach Reiseland und Immunstatus des Patienten unterscheiden sich die Krankheitsbilder. Die Infektion bildet sich in 90 % der Fälle als kutane Leishmaniasis aus, kann sich aber auch an den inneren Organen manifestieren (viszerale Leishmaniasis).
openaire   +4 more sources

Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients

Journal of Tropical Medicine, 2013
Visceral leishmaniasis (VL) is a parasitic disease characterized by immune suppression. Successful treatment is usually followed by immune reconstitution and a dermatosis called post-Kala-azar dermal leishmaniasis (PKDL).
Eltahir Awad Gasim Khalil, Selma Abdelmoneim Khidir, Ahmed Mudawi Musa, Brema Younis Musa, Mona Elfaki Eltahir Elfaki, Abdelgadir Mohamed Yousif Elkadaru, Edward Zijlstra, Ahmed Mohamed El-Hassan   +7 more
doaj   +1 more source

Life Cycle Stage-Specific Accessibility of Leishmania donovani Chromatin at Transcription Start Regions

mSystems, 2021
Leishmaniacistrans
Janne Grünebast, Stephan Lorenzen, Julia Zummack, Joachim Clos   +3 more
doaj   +3 more sources

Treatment-Based Strategy for the Management of Post-Kala-Azar Dermal Leishmaniasis Patients in the Sudan

Journal of Tropical Medicine, 2013
Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that affects more than 50% of successfully treated visceral leishmaniasis (VL) patients in Sudan.
A. M. Musa, E. A. G. Khalil, B. M. Younis, M. E. E. Elfaki, M. Y. Elamin, A. O. A. Adam, H. A. A. Mohamed, M. M. M. Dafalla, A. A. Abuzaid, A. M. El-Hassan   +9 more
doaj   +1 more source

Poor adherence is a major barrier to the proper treatment of cutaneous leishmaniasis: A case-control field assessment in Iran

International Journal for Parasitology: Drugs and Drug Resistance, 2023
Leishmaniasis is an overlooked, poverty-stricken, and complex disease with growing social and public health problems. In general, leishmaniasis is a curable disease; however, there is an expansion of unresponsive cases to treatment in cutaneous ...
Mehdi Bamorovat, Iraj Sharifi, Setareh Agha Kuchak Afshari, Ali Karamoozian, Amirhossein Tahmouresi, Amireh Heshmatkhah, Ehsan Salarkia, Ahmad Khosravi, Maryam Hakimi Parizi, Maryam Barghi   +9 more
doaj   +1 more source

The recombinant cysteine proteinase B (CPB) from Leishmania braziliensis and its domains: promising antigens for serodiagnosis of cutaneous and visceral leishmaniasis in dogs. [PDF]

, 2019
Leishmaniasis represents a group of parasitic diseases caused by a protozoan of the genus Leishmania and is widely distributed in tropical and subtropical regions.
Basombrío, Manuel Alberto, Bivona, Augusto Ernesto, Cardoso Landaburu, Alejandro Cesar, Cazorla, Silvia Ines, Cerny, Natacha, Czentner Colomo, Lucas, Estevez, José Octavio, Malchiodi, Emilio Luis, Marco, Jorge Diego, Nevot, María Cecilia, Sanchez Alberti, Andrés   +10 more
core   +1 more source

Laryngeal Leishmaniasis [PDF]

International Archives of Otorhinolaryngology, 2012
Introduction: Leishmaniasis is classified into three clinical presentations: visceral, coetaneous and mucocutaneous. The latter is usually secondary to hematogenous spread after months or years of skin infection and can manifest as infiltrative lesions, ulcerated or vegetating in nose, pharynx, larynx and mouth, associated or not with ...
Moraes, Bruno Teixeira de, Amorim Filho, Francisco de Souza, Caporrino Neto, José, Saraceni Neto, Paulo, Melo Júnior, José Elson Santiago de   +4 more
openaire   +4 more sources

Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment

Annals of Saudi Medicine, 2014
BACKGROUND AND OBJECTIVES: Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In Sudan, VL is caused by L donovani. Most drugs used to treat VL, especially pentavalent antimony compounds (sodium stibogluconate, SSG),
Abubakr O. A. Adam, Mohamed M. M. Dafalla, Hatim A. A. Mohammed, Mohamed Y. Elamin, Brima M. Younis, Mona E. E. Elfaki, Ahmed M. Musa, Ahmed M. Elhassan, Eltahir A. G. Khalil   +8 more
doaj   +1 more source

Low castes have poor access to visceral leishmaniasis treatment in Bihar, India [PDF]

, 2012
Objectives  Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases in the country. A large proportion of the poor rural communities where VL is endemic are marginalized by their socio-economic status, intrinsically ...
Alvar, Babu, Barratt, Boelaert, Cerf, Collin, de Onis, Dedet, Desjeux, Dye, Hasker, Heymann, India., G.o, Mondal, Ostyn, Ranjan, Sinha, Thakur, Van de Poel, WHO, WHO, WHO, WHO/UNICEF   +22 more
core   +2 more sources

Leishmaniasis [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
SummaryLeishmaniasis is a clinically heterogeneous group of diseases, caused by infection with protozoa of the genus Leishmania. The aggressiveness of the individual species, their organ preference and the host immune status determine disease course.
openaire   +2 more sources